Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 5/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | GABRP | O00591 | 3/20 | 0.41 |
| ▸ | GABRD | O14764 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.41 |
| ▸ | GABRE | P78334 | 3/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887943 | 0.83 | MEN1 (0.42) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL12344889 | 0.82 | KDM4E (0.38) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL4551276 | 0.76 | FLT3 (0.49) | KDM4EALDH1A1HPGDSRCEGFR | |
| SCHEMBL12344899 | 0.74 | SRC (0.46) | KDM4EALDH1A1HPGDSRCMEN1 | |
| SCHEMBL2887197 | 0.73 | HTR6 (0.41) | MEN1KMT2APOLBGAAMAPT | |
| SCHEMBL2885831 | 0.72 | MAPT (0.35) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL2887785 | 0.70 | MAOA (0.41) | ALDH1A1GAAL3MBTL1 | |
| SCHEMBL14577313 | 0.69 | PABPC1 (0.59) | KDM4EALDH1A1HPGDSRCEGFR | |
| SCHEMBL15987388 | 0.68 | SRC (0.56) | KDM4EALDH1A1HPGDSRCEGFR | |
| SCHEMBL30883973 | 0.68 | SRC (0.56) | KDM4EALDH1A1HPGDSRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035429-B1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON INC (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2035429-B1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON INC (US) | 2012-09-19 | — | — | EP | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| EP-2035429-A1 | FUSED [d]PYRIDAZIN-7-ONES | Cephalon, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007149557-A1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007149557-A1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CDK5, CDK5R1, CDK7 | KDM4E 1305/4885ALDH1A1 2124/4885HPGD 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.